Sökning: L773:1018 8665 OR L773:1421 9832 >
Efficacy results of...
Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet (R)/Dovobet (R)/Taclonex (R)) in the treatment of psoriasis vulgaris
-
Kragballe, K. (författare)
-
Austad, J. (författare)
-
Barnes, L. (författare)
-
visa fler...
-
Bibby, A. (författare)
-
de la Brassinne, M. (författare)
-
Cambazard, F. (författare)
-
Fleming, C. (författare)
-
Heikkila, H. (författare)
-
Williams, Z. (författare)
-
Rey, J. Peyri (författare)
-
- Svensson, Åke (författare)
- Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine
-
Toole, J. (författare)
-
Wozel, G. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2006-12-18
- 2006
- Engelska.
-
Ingår i: Dermatology. - : S. Karger AG. - 1421-9832 .- 1018-8665. ; 213:4, s. 319-326
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: The calcipotriol/betamethasone dipropionate two-compound product is safe and effective in the short-term treatment of psoriasis. Objective: The primary objective was to investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks. The efficacy results are presented here. Methods: Six hundred and thirty-four patients were randomised double-blind to treatment (once daily, when required) with either: 52 weeks of two-compound product (two-compound group), 52 weeks of alternating 4-week periods of two-compound product and calcipotriol (alternating group), or 4 weeks of two-compound product followed by 48 weeks of calcipotriol (calcipotriol group). Results: There was a trend towards a difference between treatments from the overall treatment effect for the percentage of satisfactory responses for each patient during the study (p = 0.071). This appeared to be due to the comparison of the two-compound and calcipotriol groups (p = 0.025). Conclusion: There was a trend towards the efficacy of the two-compound product used for up to 52 weeks being better than that of 4 weeks of the two-compound product followed by 48 weeks of calcipotriol.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)
Nyckelord
- Taclonex (R)
- Dovobet (R)
- Daivobet (R)
- psoriasis
- two-compound product
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Kragballe, K.
-
Austad, J.
-
Barnes, L.
-
Bibby, A.
-
de la Brassinne, ...
-
Cambazard, F.
-
visa fler...
-
Fleming, C.
-
Heikkila, H.
-
Williams, Z.
-
Rey, J. Peyri
-
Svensson, Åke
-
Toole, J.
-
Wozel, G.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Dermatologi och ...
- Artiklar i publikationen
-
Dermatology
- Av lärosätet
-
Lunds universitet